Home > Press > NanoViricides, Inc. Added to the Ludlow Biotech Index
Abstract:
NanoViricides, Inc. (OTC BB: NNVC.OB) a development stage company that is creating special purpose nanomaterials for the treatment of viral infections, today announced that the company has been added to the Ludlow Biotech Index.
NanoViricides, Inc. Added to the Ludlow Biotech Index
WEST HAVEN, CT | Posted on July 21st, 2008
Tom Bustamante, the Managing Partner of Ludlow BioVentures commented, "NanoViricides utilizes creative and unique nanomaterials for targeting and destroying viruses. The company's nanoviricides™ drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. NanoViricides, Inc. is thus creating treatments that need to be given only to patients that contract a viral disease, as opposed to vaccines, which must be given to substantially the entire population to prevent the occurrence of an epidemic. Nanoviricide drugs form a novel class of drugs, that is complementary to other existing viral therapies. This unique approach makes NNVC an interesting play in the field of viral therapy, and should provide for additional depth to our biotechnology stock index."
The Ludlow Biotech Index is a diverse basket of biotechnology stocks, that includes well established biotech stocks such as Amgen, Biogen-Idec, and Genzyme. This index provides institutional investors a means to track and trade a basket of small cap biotechnology stocks, with reduced risk through diversification. The Ludlow Biotech Index is owned and operated by Ludlow Capital Group, Inc.
For additional information on the Ludlow Biotech Index and its components visit www.ludlowcapital.com/indices/biotech/
Disclosure
NanoViricides, Inc. is not a client of Ludlow BioVentures. NanoViricides, Inc. has not paid any compensation to Ludlow for inclusion of NNVC in the Ludlow Biotech Index.
About Ludlow BioVentures:Based in New York City, Ludlow BioVentures is a venture capital and research advisory firm with a specific focus on the biotechnology sector. The goal of the firm is to promote investments into biotech ventures worldwide. Ludlow BioVentures owns and operates the Ludlow Biotech Index, which tracks a wide basket of US traded large and small cap biotechnology stocks. www.ludlowcapital.com/bioventures/
####
About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for treatment of viral infections. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.
For more information, please click here
Contacts:
NanoViricides, Inc.
Amanda Schuon
310-550-7200
Copyright © Business Wire 2008
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
News and information
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
Beautiful "flowers" self-assemble in a beaker: Elaborate nanostructures blossom from a chemical reaction perfected at Harvard May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013
Investments/IPO's/Splits
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
Harris & Harris Group Notes the Sale of a Second D-Wave Quantum Computer May 16th, 2013
Nanometrics Announces Upcoming Investor Events May 14th, 2013
Nanostart-holding New Asia Investments invests in breakthrough water projects May 13th, 2013
Nanomedicine
Nanotechnology could help fight diabetes: Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed May 16th, 2013
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Pitt Chemists Demonstrate Nanoscale Alloys So Bright They Could Have Potential Medical Applications: “Think about a particle that will not only help researchers detect cancer sooner but be used to treat the tumor, too.” May 15th, 2013
Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells May 15th, 2013
Announcements
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
NIA Public Briefing: Nanotechnology and the Council of Europe May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013